CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02320058
NCT02320058Phase 2Completed
CompareCT.gov

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Bristol-Myers Squibb·interventional·Posted Dec 19, 2014·Updated Oct 5, 2021

In Brief

A Phase 2 clinical trial evaluating Ipilimumab and Nivolumab for Melanoma. Completed, enrolled 119 participants across 36 sites.

Detailed Summary

This is a study of Nivolumab combined with Ipilimumab followed by Nivolumab by itself for the treatment of patients with Melanoma that has spread to the brain. Patients with histologically confirmed Malignant Melanoma and asymptomatic brain metastases are eligible for the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 19, 2014
Enrollment StartMar 5, 2015
Primary CompletionSep 8, 2020
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 11.5 years ago

Interventions

Ipilimumabdrug

Nivolumabdrug